$ENTB Ongoing objectives include gene silencing for treating cancer with immunotherapy, modulating key molecular processes in cancer stem cells through Zander’s patented molecular targeting approaches and repairing damaged bone marrow in animals with aplastic anemia and bone marrow suppression due to side effects of chemotherapy/radiotherapy-treated cancer patients.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.